Literature DB >> 25047752

Parvovirus glycan interactions.

Lin-Ya Huang1, Sujata Halder1, Mavis Agbandje-McKenna2.   

Abstract

Members of the Parvoviridae utilize glycan receptors for cellular attachment and subsequent interactions determine transduction efficiency or pathogenic outcome. This review focuses on the identity of the glycan receptors utilized, their capsid binding footprints, and a discussion of the overlap of these sites with tropism, transduction, and pathogenicity determinants. Despite high sequence diversity between the different genera, most parvoviruses bind to negatively charged glycans, such as sialic acid and heparan sulfate, abundant on cell surface membranes. The capsid structure of these viruses exhibit high structural homology enabling common regions to be utilized for glycan binding. At the same time the sequence diversity at the common footprints allows for binding of different glycans or differential binding of the same glycan.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25047752      PMCID: PMC4149944          DOI: 10.1016/j.coviro.2014.05.007

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  102 in total

1.  Haemagglutination by parvovirus B19.

Authors:  K E Brown; B J Cohen
Journal:  J Gen Virol       Date:  1992-08       Impact factor: 3.891

2.  Mapping of the fibrotropic and lymphotropic host range determinants of the parvovirus minute virus of mice.

Authors:  E M Gardiner; P Tattersall
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

3.  Erythrocyte P antigen: cellular receptor for B19 parvovirus.

Authors:  K E Brown; S M Anderson; N S Young
Journal:  Science       Date:  1993-10-01       Impact factor: 47.728

Review 4.  Antineoplastic activity of parvoviruses.

Authors:  J Rommelaere; J J Cornelis
Journal:  J Virol Methods       Date:  1991-08       Impact factor: 2.014

5.  Multiple amino acids in the capsid structure of canine parvovirus coordinately determine the canine host range and specific antigenic and hemagglutination properties.

Authors:  S F Chang; J Y Sgro; C R Parrish
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

6.  Structure determination of feline panleukopenia virus empty particles.

Authors:  M Agbandje; R McKenna; M G Rossmann; M L Strassheim; C R Parrish
Journal:  Proteins       Date:  1993-06

7.  Mutations adjacent to the dimple of the canine parvovirus capsid structure affect sialic acid binding.

Authors:  D P Barbis; S F Chang; C R Parrish
Journal:  Virology       Date:  1992-11       Impact factor: 3.616

8.  Infectious entry pathway for canine parvovirus.

Authors:  S Basak; H Turner
Journal:  Virology       Date:  1992-02       Impact factor: 3.616

9.  Molecular characterization of two strains of the avian adeno-associated virus (AAAV).

Authors:  M Hess; G Paul; S Kling; G Monreal
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

10.  Two amino acid substitutions within the capsid are coordinately required for acquisition of fibrotropism by the lymphotropic strain of minute virus of mice.

Authors:  L J Ball-Goodrich; P Tattersall
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

View more
  52 in total

1.  Chemical Modulation of Endocytic Sorting Augments Adeno-associated Viral Transduction.

Authors:  Garrett E Berry; Aravind Asokan
Journal:  J Biol Chem       Date:  2015-11-02       Impact factor: 5.157

2.  Examination and Reconstruction of Three Ancient Endogenous Parvovirus Capsid Protein Gene Remnants Found in Rodent Genomes.

Authors:  Heather M Callaway; Suriyasri Subramanian; Christian A Urbina; Karen N Barnard; Robert A Dick; Carol M Bator; Susan L Hafenstein; Robert J Gifford; Colin R Parrish
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

3.  Mapping Antigenic Epitopes on the Human Bocavirus Capsid.

Authors:  Shweta Kailasan; Jamie Garrison; Maria Ilyas; Paul Chipman; Robert McKenna; Kalle Kantola; Maria Söderlund-Venermo; Indrė Kučinskaitė-Kodzė; Aurelija Žvirblienė; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

4.  Gene delivery to rat and human Schwann cells and nerve segments: a comparison of AAV 1-9 and lentiviral vectors.

Authors:  S A Hoyng; F De Winter; S Gnavi; L van Egmond; C L Attwell; M R Tannemaat; J Verhaagen; M J A Malessy
Journal:  Gene Ther       Date:  2015-05-04       Impact factor: 5.250

Review 5.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

6.  Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2.

Authors:  Antonette Bennett; Annahita Keravala; Victoria Makal; Justin Kurian; Brahim Belbellaa; Rangoli Aeran; Yu-Shan Tseng; Duncan Sousa; John Spear; Mehdi Gasmi; Mavis Agbandje-McKenna
Journal:  J Struct Biol       Date:  2019-12-16       Impact factor: 2.867

7.  Unique glycan signatures regulate adeno-associated virus tropism in the developing brain.

Authors:  Giridhar Murlidharan; Travis Corriher; H Troy Ghashghaei; Aravind Asokan
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

8.  A Preclinical Study in Rhesus Macaques for Cystic Fibrosis to Assess Gene Transfer and Transduction by AAV1 and AAV5 with a Dual-Luciferase Reporter System.

Authors:  William B Guggino; Janet Benson; JeanClare Seagrave; Ziying Yan; John Engelhardt; Guangping Gao; Thomas J Conlon; Liudmila Cebotaru
Journal:  Hum Gene Ther Clin Dev       Date:  2017-07-19       Impact factor: 5.032

9.  Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain.

Authors:  Giridhar Murlidharan; Andrew Crowther; Rebecca A Reardon; Juan Song; Aravind Asokan
Journal:  JCI Insight       Date:  2016-09-08

Review 10.  Systemic delivery of adeno-associated viral vectors.

Authors:  Dongsheng Duan
Journal:  Curr Opin Virol       Date:  2016-07-25       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.